This study focuses on patients with non-small cell lung cancer (NSCLC) who have had their cancer surgically removed and are at stage II-IIIA of the disease. The study specifically looks at patients whose tumor cells show a certain protein marker called PD-L1. These patients have not received chemotherapy after their surgery.

The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.